celecoxib and leucine

celecoxib has been researched along with leucine in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	4 (57.14)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Badawi, AF; Badr, MZ; Eldeen, MB; Liu, Y; Ross, EA	1
Bakhle, YS; de Francischi, JN; Dos Reis, WG; Duarte, ID; Lima, PP; Rezende, RM	1
Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J	1
Filipowicz, A; Markowicz, J; Misiorek, M; Pieńkowska, N; Uram, Ł; Wałajtys-Rode, E; Wołowiec, S	1
Anderson, AJ; Dong, L; Malkowski, MG	1
Filipowicz-Rachwał, A; Markowicz, J; Misiorek, M; Pichla, M; Uram, Ł; Wałajtys-Rode, E; Wołowiec, S	1
Chen, SZ; Li, G; Ni, J; Shang, Y; Wang, A; Wang, C; Wang, W	1

Trials

1 trial(s) available for celecoxib and leucine

Article	Year
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. BMC cancer, 2011, Nov-23, Volume: 11 Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Eicosapentaenoic Acid; Feasibility Studies; Female; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; New Zealand; Patient Satisfaction; Prospective Studies; Pyrazoles; Resistance Training; Sulfonamides	2011

Article

Year

A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

BMC cancer, 2011, Nov-23, Volume: 11

Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Eicosapentaenoic Acid; Feasibility Studies; Female; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; New Zealand; Patient Satisfaction; Prospective Studies; Pyrazoles; Resistance Training; Sulfonamides

2011

Other Studies

6 other study(ies) available for celecoxib and leucine

Article	Year
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer research, 2004, Feb-01, Volume: 64, Issue:3 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Carcinogens; Celecoxib; Cell Cycle; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Female; Fluorenes; Isoenzymes; Leucine; Mammary Neoplasms, Experimental; Methylnitrosourea; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Transcription Factors	2004
The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain, 2009, Volume: 142, Issue:1-2 Topics: Analgesics, Opioid; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Immunologic Factors; Inflammation; Injections, Intraventricular; Leucine; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Reaction Time; Sulfonamides; Time Factors	2009
Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Nov-01, Volume: 124 Topics: Antineoplastic Agents; Biotinylation; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 2 Inhibitors; Dendrimers; Humans; Leucine; Neoplasms; PPAR gamma	2018
Arg-513 and Leu-531 Are Key Residues Governing Time-Dependent Inhibition of Cyclooxygenase-2 by Aspirin and Celebrex. Biochemistry, 2019, 09-24, Volume: 58, Issue:38 Topics: Animals; Arachidonic Acid; Arginine; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Enzyme Assays; Histidine; Hydroxyeicosatetraenoic Acids; Leucine; Mutagenesis, Site-Directed; Recombinant Proteins; Sf9 Cells; Stereoisomerism; Substrate Specificity; Time Factors	2019
The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro. Molecules (Basel, Switzerland), 2019, Oct-22, Volume: 24, Issue:20 Topics: Antineoplastic Agents; Apoptosis; Biotinylation; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendrimers; Dinoprostone; Fibroblasts; Glioblastoma; Humans; Keratinocytes; Leucine; Necrosis; PPAR gamma; Tumor Suppressor Protein p53	2019
Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer. The Journal of pharmacology and experimental therapeutics, 2022, Volume: 382, Issue:2 Topics: Apoptosis; Celecoxib; Cell Cycle; Colorectal Neoplasms; Humans; Leucine; RNA, Messenger; Thymidine Kinase	2022